NTLA · Intellia Therapeutics, Inc.
$12.09
+0.03 (+0.25%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$1.65B
Shares
140.13M
Volume · Sep 30
5.32M
Avg daily vol (3M)
3.93M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.06
Open$11.96
Day$11.75–12.24
52W close$8.04–27.98
Avg vol 30d4.0M
Short int46.7M · 33.3% float · 14.1d
Short vol55%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 16, 2026
Est · unconfirmed
· in 7 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$59.51M
Trailing 12 months
Net income (TTM)
−$399.98M
Trailing 12 months
Revenue growth YoY
-46.2%
Year over year
Operating margin
-711.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-21.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$437.76M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+28.7%
Year over year · more shares
Price change (1Y)
-28.9%
Trailing year
Short interest
33.3%
Latest settlement · 14.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Intellia reported positive Phase 3 HAELO data for lonvo-z in HAE supporting a potential first-half 2027 U.S. launch, resumed enrollment in nex-z Phase 3 ATTR trials and identified an HLA allele linked to liver transaminase elevations, and ended Q2 with $628.4M in cash (runway into 2028) but a wider net loss of $106.6M.
Bullish
- + Expects FDA BLA acceptance for lonvo-z in 2H 2026 with a planned U.S. launch in 1H 2027, supported by completed commercial team hiring.
- + Resumed enrollment/dosing in both nex-z Phase 3 trials in Q2 with Magnitude-2 enrollment expected to complete in 2H 2026.
- + Identified HLA C0501 allele linked to severe liver transaminase elevations, enabling mitigation and patient selection, with management framing it as confidence-building.
- + Cash position strengthened to $628.4M with runway expected at least into 2028, following a $195M equity raise.
Bearish
- − Collaboration revenue fell to $7.7M from $14.2M, driven by reduced revenue from Regeneron.
- − G&A expenses rose to $37.8M from $27.2M as commercial infrastructure and legal costs increased.
- − Disappointing competitor CardioTransform data raises uncertainty for combination ATTR strategy and may require Magnitude trial design changes.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
+1%
above
RSI (14)
49
neutral
MACD trend
Negative
52-week position
20%
mid-range
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−13%
trailing
YTD return
+34%
this year
Relative strength
−25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
+7% holders QoQ · +53 funds added
Insider flow
Distributing
Net -$91.2K over 90 days · 100% sells
Short interest
Rising
33.31% of float · ▲ +6.3% MoM · 14.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
333 holders — near 3-yr high, broad support
Squeeze score
81
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
EPS growth
+27%
Y/Y
Free cash flow
$-395.9M
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
20%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
+7% holders QoQ · +53 funds added
Insider flow
Distributing
Net -$91.2K over 90 days · 100% sells
Short interest
Rising
33.31% of float · ▲ +6.3% MoM · 14.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
333 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8
Now $12 · 20%
Range high $28
vs 200-day avg -6%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| all-cause mortality rate for matched NAC ATTR-CM cohort | 12.7 | the three months ended June 30, 2026 filing | — |
| all-cause mortality rate for nex-z treated ATTR-CM patients (post-hoc analysis) | 3.9 | the three months ended June 30, 2026 filing | — |
| mean monthly attack rate in the lonvo-z arm (HAELO, weeks 5 to 28) | 0.26 | the three months ended June 30, 2026 filing | — |
| mean monthly attack rate in the placebo arm (HAELO, weeks 5 to 28) | 2.1 | the three months ended June 30, 2026 filing | — |
| NAC matched ATTR-CM cohort size (post-hoc analysis) | 1,792 | the three months ended June 30, 2026 filing | — |
| patients enrolled in HAELO Phase 3 trial | 80 | the three months ended June 30, 2026 filing | — |
| patients entirely attack free and therapy free in the lonvo-z arm (HAELO, weeks 5 to 28) | 62% | the three months ended June 30, 2026 filing | — |
| patients entirely attack free and therapy free in the placebo arm (HAELO, weeks 5 to 28) | 11% | the three months ended June 30, 2026 filing | — |
| patients in MAGNITUDE Phase 3 trial | 1,200 | the three months ended June 30, 2026 filing | — |
| patients in MAGNITUDE-2 Phase 3 trial | 50 | the three months ended June 30, 2026 filing | — |
| Phase 1 ATTRv-PN patients reaching 36 months of follow-up | 12 | the three months ended June 30, 2026 filing | — |
| Phase 1 ATTRv-PN patients receiving a one-time dose of 0.3 mg/kg or higher | 33 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NTLA
this stock
Intellia Therapeutics, Inc.
|
$1.65B | +34.1% | +16.9% | — | 33.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NTLA | -2.2% | -4.9% | -12.8% | -5.3% | +34.2% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -1.5% | -5.0% | -25.0% | -4.7% | +22.3% |
Key facts
CIK
1652130
CUSIP
45826J105
13F (30d)
11 filings
7 filers
Visit website
Investor relations